# Smith and Nephew (SNN) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/SNN
## Company Profile
- Ticker: SNN
- Exchange: NYSE
- Sector: MedTech
- Location: United Kingdom and listed in the U
- Tags: MedTech
## Stock Data
- Close: 26.96 USD
- Market cap: 12475206513.44 USD
- Last updated: 2026-10-08
## Business Overview
### Global Medical Technology Company
Smith+Nephew develops medical technologies for the repair, regeneration, and replacement of soft and hard tissue. It operates through Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management.
### Orthopaedics
The Orthopaedics business provides knee and hip implants, trauma products, enabling technologies, and robotic-assisted surgery systems. Its CORI platform and implant portfolio support both hospital and ambulatory joint-replacement procedures.
### Sports Medicine and ENT
Sports Medicine and ENT includes arthroscopic repair systems, biologic augmentation, joint-preservation products, visualization, fluid management, and ear, nose, and throat technologies. Products such as REGENETEN and FASTSEAL address soft-tissue repair and procedural efficiency.
### Advanced Wound Management
The wound-care portfolio includes negative-pressure wound therapy, advanced dressings, enzymatic debridement, and skin-substitute products. Brands such as PICO, ALLEVYN, and SANTYL serve acute and chronic wounds across hospitals, clinics, and home-care settings.
### Innovation and Procedure Expansion
Smith+Nephew grows through new implant designs, robotic capabilities, biologic repair products, and next-generation wound-care systems. Its commercial model combines product launches with surgeon education and broader deployment of procedure-specific instrument sets.
## Why The Stock Is Moving

As of Oct 8, 2026, SNN closed up 0.26% at $26.96. No new same-company headline was identified in the current news window.

## Future Catalysts

- Expanded European launch of ALLEVYN COMPLETE CARE and launch of the next-generation LEAF wound-monitoring platform in the second half of 2026.
- Launch of the cementless version of the LANDMARK knee system in the second half of 2026.

## Recent News
- 2016-12-21 08:30 EST — [Smith & Nephew wins prestigious Galien Award for PICO Negative Pressure Wound Therapy innovation](https://biopharmsignal.com/news/SNN/smith-nephew-wins-prestigious-galien-award-for-pico-negative-pressure-wound-ther-245424f5) — Source: Smith and Nephew
- 2004-12-22 10:46 EST — [Smith & Nephew Announcement Dates For 2005 And Details Of The Briefing At The American Academy Of Orthopaedic Surgeons](https://biopharmsignal.com/news/SNN/smith-nephew-announcement-dates-for-2005-and-details-of-the-briefing-at-the-amer-6c63ac89) — Source: Smith and Nephew
- 2004-12-20 17:15 EST — [Smith & Nephew Announces Excess Insurers Decline Coverage](https://biopharmsignal.com/news/SNN/smith-nephew-announces-excess-insurers-decline-coverage-8a229ba0) — Source: Smith and Nephew
- 2004-11-17 12:01 EST — [Smith & Nephew Plc announces IFRS Presentation](https://biopharmsignal.com/news/SNN/smith-nephew-plc-announces-ifrs-presentation-0cab6a63) — Source: Smith and Nephew
- 2004-11-16 18:07 EST — [Timing of Smith & Nephew plc International Financial Reporting Standards 'IFRS' Presentation](https://biopharmsignal.com/news/SNN/timing-of-smith-nephew-plc-international-financial-reporting-standards-ifrs-pres-d74784a8) — Source: Smith and Nephew